fda warning letters bpc-157 peptide not approved BPC 157 Banned: Key Facts on the Latest Decision FDA Committee Votes to Ease

J-codes and drug billing with CPT 96372 Because 96372 covers only the injection technique, the drug must be billed on a separate line using a HCPCS Level II J-code

In most Crohns flare admissions, K50.x code is principal

This therapy should not be used during pregnancy or while breastfeeding

Active cancer or history of malignancy Pregnancy or breastfeeding Known peptide allergies Athletes subject to anti-doping testing (WADA prohibited) Raynauds disease or phenomenon Cold urticaria (hives from cold) Uncontrolled hypertension Peripheral vascular disease Open wounds (for local application) Pregnancy Cardiovascular conditions Diabetes (especially with neuropathy) Current infections Immunosuppression Blood clotting disorders Quality control issues represent perhaps the greatest practical risk with BPC-157